Biotech

EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study

Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?

TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show

Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?

TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show

BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion

Hims & Hers: The Next Amazon? Novo Nordisk Might Be Prime Delivery

BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion

Hims & Hers: The Next Amazon? Novo Nordisk Might Be Prime Delivery

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial

Biotech Recent News

Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results

Pasithea shares rise as early Phase 1 data of PAS-004 shows strong pERK inhibition and tumor shrinkage in advanced cancer patients.

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

BioCryst posted $134.2 million in Q1 revenue, raised 2025 Orladeyo guidance, and now expects full-year profitability and positive cash flow.

Vertex Pharmaceuticals Stock Falls On Q1 Earnings, Revenue Miss — Company Raises Low End Of FY25 Revenue Guidance

Vertex Pharmaceuticals reports first-quarter financial results after the market close on Monday. Here's a look at the key highlights from the period.

Vertex Has Lost Some Sizzle Into Q1 Earnings - Can Alyftrek, Journavx Reignite The Momentum?

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports Q1 earnings with $4.32 EPS and $2.85B revenue. Stock up 25.48% in past year, charts show bullish trend.

Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?

FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases.

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

Axsome beat Q1 expectations with $121.5 million in revenue and strong Auvelity sales as it prepares Symbravo's U.S. launch and advances key drug programs.

Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk

Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained despite early launch volatility.

Amgen's Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data

Analysts highlight MariTide's upcoming updates and near-term catalysts, while Amgen's price targets shift amid steady outlook and investor caution.

FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months

FDA extended the aficamten decision deadline to Dec. 26 after classifying the REMS submission as a major amendment to the NDA review.

Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market potential.

Why Is Novo Nordisk Stock Trading Higher On Friday?

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease affecting patients with obesity.

AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma

AstraZeneca's Breztri met primary goals in four asthma trials, including KALOS, LOGOS, LITHOS, and VATHOS, involving over 5,000 patients.

Elon Musk Says Neuralink Will 'Ultimately' Be Available To All As FDA Grants Breakthrough Status For Speech-Restoring Brain Tech

Elon Musk announced plans to make Neuralink's brain-computer interface technology "widely available" following the company's receipt of Breakthrough Device Designation from the FDA for restoring communication in severely speech-impaired individuals.